雜志介紹

Cancer Science雜志介紹

《Cancer Science》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱癌癥科學(xué)，本刊主要出版、報(bào)道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為4.5，最新CiteScore 指數(shù)為9.9。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma

  Author: Jiang, Jinxing; Xiang, Jing; Chen, Mengping; Wan, Yike; Zhong, Lu; Han, Xiaofeng; Chen, Xiaotong; Wang, Junying; Xiao, Fei; Liu, Jia; Li, Hua; Huang, Honghui; Hou, Jian

• Targeting the PTP1B-Bcr-Abl1 interaction for the degradation of T315I mutant Bcr-Abl1 in chronic myeloid leukemia

  Author: Elgehama, Ahmed; Wang, Yixuan; Yu, Ying; Zhou, Lin; Chen, Zhixiu; Wang, Liwei; Sun, Lijun; Gao, Jian; Yu, Biao; Shen, Yan; Xu, Qiang

• Hypoxia-induced CXC chemokine ligand 14 expression drives protumorigenic effects through activation of insulin-like growth factor-1 receptor signaling in glioblastoma

  Author: Wei, Sung-Tai; Chiang, Jung-Ying; Wang, Hwai-Lee; Lei, Fu-Ju; Huang, Yen-Chih; Wang, Chi-Chung; Cho, Der-Yang; Hsieh, Chia-Hung

• METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer

  Author: Xu, Xiaofeng; Zhang, Peiru; Huang, Yangle; Shi, Weizhong; Mao, Jingfang; Ma, Ningyi; Kong, Lin; Guo, Lin; Liu, Jinlong; Chen, Jian; Lu, Renquan

英文介紹

Cancer Science雜志英文介紹

Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.

Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.